H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target

H.C. Wainwright reiterated its Buy rating and $2.50 price target for Medicenna Therapeutics (MDNA) following the company's Q1 FY26 report, citing significant upside from its current $0.61 price. The firm noted that the Phase 1/2 ABILITY-1 study for MDNA11 remains on track for enrollment completion and top-line data by year-end 2025, with management planning further clinical data updates. While the company maintains strong liquidity and plans a new clinical program for MDNA113 in 2026 contingent on funding, InvestingPro data suggests the stock is trading near its fair value.

Analysis

H.C. Wainwright has reiterated its Buy rating and a $2.50 price target on Medicenna Therapeutics (MDNA), representing substantial potential upside from its current price of approximately $0.61. This analyst confidence is anchored in the steady progress of the company's lead asset, MDNA11, with its Phase 1/2 ABILITY-1 study on track to deliver top-line data by the end of 2025 and interim clinical updates expected before year-end. Financially, the company's $53.3 million market capitalization is supported by a strong liquidity position, evidenced by a current ratio of 4.94, which should sustain its current clinical activities. However, a key forward-looking risk is the funding dependency for its next clinical program, MDNA113, planned for 2026. A critical point of divergence for investors is the contrast between the analyst's bullish target and InvestingPro data suggesting the stock is already trading near its fair value, indicating a wide disparity in valuation methodologies and future expectations.

Key Decisions for Investors

• Investors considering a long position should view the upcoming clinical data updates for MDNA11 before year-end and top-line results in 2025 as the primary near-term catalysts that could validate H.C. Wainwright's bullish price target.
• It is critical to weigh the significant discrepancy between the analyst's price target and InvestingPro's fair value assessment, which suggests the market has a more cautious view on the company's prospects.
• Risk assessment must include the company's future financing needs, particularly the explicit contingency of securing new capital to advance the MDNA113 program into clinical trials in 2026.